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Abstract
Several types of epidermal growth factor receptor (EGFR) gene alternations have been observed in human tumors.
Here we present a novel EGFR variant with aberrant splicing of exon 4 (named as de4 EGFR). Variant-specific poly-
merase chain reaction showed that de4 EGFR was expressed in some glioma (4/40), prostate cancer (3/11), and
ovarian cancer (3/9) tissues but not in tissues adjacent to tumors or normal tissues. de4 EGFR displayed an enhanced
transformation and a higher metastasis-promoting capacity in comparison to wild-type EGFR. With minimal EGF-
binding activity, de4 EGFR underwent ligand-independent autophosphorylation and self-dimerization. Moreover, in
serum-starved condition, de4 EGFR expression in U87 MG cells significantly upregulated the extracellular signal–
regulated kinase and AKT phosphorylation and expression of JUN and Src. Importantly, E-cadherin expression
was barely detectable in the U87 MG cells expressing de4 EGFR and restored expression of E-cadherin in these cells
inhibited their metastatic behaviors. Taken together, we identified a novel EGFR variant with increased metastasis-
promoting activity that may become a promising new target for cancer therapy.
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Introduction
The epidermal growth factor receptor (EGFR) is a 170-kDa trans-
membrane glycoprotein that belongs to the receptor tyrosine kinase
family of growth factor receptors. Owing to its important contribu-
tions to tumor cell survival, proliferation, and motility, EGFR has been
associated with a large number of human malignancies such as breast
cancer, lung cancer, brain cancer, prostate cancer, and liver cancer [1–
7]. Overexpression, deletion, and mutation of the EGFR gene are
the most common mechanisms by which EGFR exerts influence on
tumorigenesis [8–10].
Coding sequence alterations of EGFR are frequently found in many
types of human tumors [11–15]. In most cases, the EGFR variants are
likely to be generated through genomic deletion. Conversely, in some
instances involving the deletion or rearrangement of the intact exon(s),
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variants may occur as a consequence of alternative splicing [16]. Most
variants with deletions in the extracellular domain correlate with a poor
prognosis. These variants, although sometimes having reduced ligand-
binding capacity, generally are constitutively active and mediate dif-
ferent signaling transduction pathways, thus giving the tumor cells a
growth advantage and increased malignant potential [17,18].
The most common EGFR variant is the type III EGFR deletion
mutant EGFRvIII (also called Δ801EGFR or de2-7 EGFR), which
has an in-frame deletion of exons 2 to 7. EGFRvIII has been detected
in 16% of non–small cell lung carcinoma cells, 57% of high-grade
gliomas, 24% to 67% of glioblastomas, and 42% of head and neck
squamous cell carcinomas [19–21]. Despite its frequent occurrence,
the expression of EGFRvIII is restricted to tumor cells, thus making
EGFRvIII an ideal target for anticancer therapy. Currently, several
monoclonal antibodies and vaccines directed against EGFRvIII are un-
dergoing preclinical and clinical trials [22–24]. Recently, a phase 2
multicenter trial assessing an EGFRvIII-targeted peptide vaccine was
undertaken; patients who received this vaccine had significantly longer
overall survival than the control group [25].
With the exception of EGFRvIII, the occurrence of variants in the
extracellular domain of EGFR has not been thoroughly studied be-
cause most of these variants only occur in exclusive tumor types with
a very low frequency of appearance [26]. The aim of this study was
to find a relatively common EGFR variant in human cancers, such
as gliomas, which often accompany amplification and alternation of
EGFR [14]. The association between the variant and tumorigenesis
would be established, and hence, the novel variant could provide a
promising cancer therapeutic target.
Materials and Methods
Cells
Mouse embryonic fibroblast cells (NIH/3T3) and human glioblastoma-
astrocytoma epithelial-like cells (U87MG) were obtained from ATCC
(Manassas, VA): NIH/3T3 cells were cultured in a Dulbecco modified
Eagle medium (DMEM; Gibco, Invitrogen, Carlsbad, CA) and supple-
mented with 10% bovine calf serum (PAA Laboratories, Dartmouth,
MA) and antibiotics (Gibco, Invitrogen). U87MG cells were cultured
in a DMEM supplemented with 10% fetal bovine serum (Gibco,
Invitrogen) and antibiotics.
Clinical Samples
Human cancer tissues were obtained along with a written informed
consent and pathology reports from hospitals and institutes as fol-
lows: Shanghai Ninth People’s Hospital Affiliated with the Shanghai
JiaoTong University School of Medicine (ovarian cancer), Huashan
Hospital (glioma), and Changhai Hospital of Shanghai (prostate can-
cer). Among the 40 gliomas, 36 cases with available clinical data are
clarified as grade 1 (n = 3), grade 2 (n = 12), grade 3 (n = 6), and grade
4 (n = 15). This study, including the use of all clinical materials, was
approved by the institutional ethics review committee of Shanghai
Cancer Institute.
Reverse Transcription–Polymerase Chain Reaction
Total RNA was extracted with TRIzol reagent (Invitrogen, Carlsbad,
CA) from tumors or from normal/adjacent tissues. Reverse transcription–
polymerase chain reaction (PCR) was performed using nested primers.
The sequences of the primers for the first round of reverse transcription–
PCR were as follows: 5′-GTATTGATCGGGAGAGCCG-3′ (forward
primer, de4-S1) and 5′-GTGGAGATCGCCACTGATG-3′ (reverse
primer, de4-AS1). EGFRvIII detection was performed using for-
ward primer 5′-ATGCGACCCTCCGGGACG-3′ and reverse primer
5′-ATTCCGTTACACACTTTGCGGC-3′.
For amplification of de4 EGFR in gliomas, an aliquot from the first
round of production was used as a template for the second round of
PCR amplification using the following primers: 5′-ATGCGACCCTC-
CGGGACG-3′ (forward primer, de4-S2) and 5′-GTGGTGGGGTT-
GTAGAGCATG-3′ (reverse primer, de4-AS2).
To selectively eliminate wild-type genes, specific PCR amplifications
were used. The principle behind this assay is shown in Figure 2A. In
short, an aliquot of first-round product was used as the template for
the second round of PCR amplification using the following primers:
5′-CCCATGAGAAATTTACAGGGC-3′ (forward primer, de4-S3)
and 5′-GTGGTGGGGTTGTAGAGCATG-3′ (reverse primer, de4-
AS2). Primer de4-S3, which spans exons 3 and 5, can selectively bind
to de4 EGFR.
All amplifications were performed with the following parameters:
25 cycles (15 seconds at 94°C, 15 seconds at 58°C, 60 seconds at
68°C) using 5 to 100 ng of DNA template, 125 μM deoxynucleotide
triphosphate, 2 pmol of each primer, and 0.25 U of KOD-Plus
DNA polymerase (Toyobo, Inc., Osaka, Japan). Amplification of
β-actin served as an internal control.
Lentivirus Production and Transduction of Target Cells
The EGFRwt and de4 EGFR sequences were amplified by PCR
(long strand amplification), confirmed by sequencing, and then in-
serted into a pWPT vector (a generous gift from Dr T. Didier, Univer-
sity of Geneva, Geneva, Switzerland) by replacing GFP to generate
pWPT-EGFRwt and pWPT-de4 EGFR. To produce virus particles,
20 μg of pWPT-EGFRwt or pWPT-de4 EGFR was transfected with
the 15 μg of packaging plasmid psPAX2 and 5 μg of G protein of
the vesicular stomatitis virus (VSV-G) envelope plasmid pMD2.G
(generous gifts from Dr T. Didier) into 293T cells using a calcium
phosphate transfection system. NIH/3T3 cells and U87MG cell were
transduced with recombinant lentiviral particles to produce polyclonal
cells with stable expression of EGFRwt and de4 EGFR. After being
confirmed by immunoblot, polyclonal cells were seeded into 96-well
plates at almost onecell per well. The monoclonal cell lines with the
same expression level of EGFRwt and de4 EGFR were then selected
and identified by fluorescence-activated cell sorter.
Immunoblot Analysis
Cells were serum-starved for 8 hours or treated with EGF (100 ng/ml,
unless stated otherwise) for 8 minutes. Proteins were separated on 10%
SDS-PAGE gels and transferred to nitrocellulose membranes (BioRad,
Hercules, CA). The following antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA): rabbit anti–human EGFR (SC-
03), rabbit anti–human pEGFR (Tyr1173) (SC-101668), rabbit anti–
human pEGFR (Tyr845) (SC-57542), rabbit anti–human extracellular
signal–regulated kinase (ERK; SC-93), rabbit anti–human AKT (SC-
8312), mouse anti–human pERK (SC-7383), rabbit anti–human JUN
(SC-1684), mouse anti–human Src (SC-8056), and mouse anti–human
pEGFR (Tyr1086) (SC-81490). Rabbit anti–human pEGFR (Tyr1068)
antibody (ab40815) and mouse anti–human pβ-catenin (Y654) anti-
body (ab24925) were purchased from Abcam (Abcam, Cambridge,
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UK). Rabbit anti–human pEGFR (Tyr992) antibody (07-821) was
purchased from Millipore (Millipore, Temecula, CA). Rabbit anti–
human pAKT (Ser473) (4060) and rabbit anti–human pSrc (Tyr416)
(2101) were purchased from Cell Signaling (Danvers, MA). The mouse
anti–human E-cadherin antibody (610182) and mouse anti–human
β-catenin antibody (610154) were purchased from BD Biosciences
(San Jose, CA). The mouse anti-GAPDH antibody was purchased
from KangChen Bio-tech (Shanghai, China). All experiments were
replicated at least two times.
Cell Proliferation Assay
Cell proliferation was measured using a CCK-8 Kit (Dojindo
Laboratories, Rockville, MD). Three hundred cells were seeded in
each well in a 96-well plate. CCK-8 solution (10 μl) was added into
100 μl of culture media, and the optical density was measured at
450 nm. Three independent experiments were performed.
Tumor Formation
Tumor growth assay and spontaneous metastasis assay were per-
formed by subcutaneous inoculation of 1 × 106 tumor cells into
6-week-old female nude mice. In the tumor growth assay, tumor
volumes were recorded until mice were killed on the 26th day. The
subcutaneous tumor weight of each mouse was recorded. In the spon-
taneous metastasis assay, mice were killed for necropsy 8 weeks later.
The lung weight of each mouse was recorded.
Colony Formation in Soft Agar
DMEM (2 ml) containing 0.7% agarose (Genentech, South San
Francisco, CA) and 10% fetal calf serum was poured into six-well
dishes. The layer was covered with a mixture of medium, agarose
(0.42%), and cells (300) in triplicates. Colonies were visualized and
counted under a microscope after 3 weeks.
Transwell Migration and Invasion Assay
Cell migration and invasion were gauged using a transwell migration
assay and a Matrigel invasion assay. For the transwell migration assay,
5 × 104 cells were suspended in 200 μl of DMEM without serum
and placed in the cell culture insert (8 μm pore size; BD Falcon, San
Jose, CA) of a companion plate (BD Falcon) with a prewarmed culture
medium containing 10% fetal bovine serum in the well. Cells were in-
cubated for 12 hours (NIH/3T3 cells) or 24 hours (U87MG cells) at
37°C in 5% CO2 and then fixed with 4% paraformaldehyde in PBS.
For Matrigel invasion assay, 1 × 105 cells were suspended in 200 μl of
DMEM without serum and were placed in the cell culture insert pre-
coated with 1 μg/μl Matrigel (BD Biosciences, San Jose, CA). A pre-
warmed culture medium containing 10% fetal bovine serum was added
to the well. Cells were incubated for 24 hours at 37°C in 5% CO2 and
were then fixed with 4% paraformaldehyde in PBS. The nonmigrated
or invaded cells on top of the membrane were gently removed with a
cotton swab. Cell migration or invasion was determined by staining
cells with 0.1% crystal violet (Sigma, St Louis, MO) and counting
the cells under a light microscope (100× magnification) in eight ran-
domly selected areas.
EGF Binding Assay
Flow cytometric binding studies were performed at 0°C in PBS
containing 0.5% BSA. A total of 200 μl of cell suspension and 50 μl
of EGF-Rho (Molecular Probes) were mixed so that the final cell
concentration was 1 × 106/ml, and the final EGF-Rho concentration
was 400 ng/ml. Autofluorescence blanks (50 μl of buffer without
EGF-Rho) were also prepared and served as control. All samples were
placed on ice in the dark for 2 hours before the measurement of cel-
lular fluorescence.
Covalent Cross-linking Analyses
Cells were grown on 10-cm plates, serum-starved for 8 hours, and
incubated with EGF (100 ng/ml) for 8 minutes. After being washed
twice with saline, cells were incubated for 20 minutes on ice in PBS
containing 2 mM BS3 (Pierce, Rockford, IL). The reaction was
quenched by adding Tris (50 mM, final concentration), and then
cells were harvested.
Statistical Analysis
Data are presented as means ± SD. After the Levene test was used
to test for equality of the variances, data were examined using an
analysis of variance (ANOVA) test and the LSD method for multi-
sample comparisons or Student’s t test for the two-sample compari-
sons A value of P < .05 was considered statistically significant.
Results
Discovery and Detection of de4 EGFR
During our analysis of aberrant EGFR in gliomas, we identified
an unexpected band that was slightly smaller than wild-type EGFR
(Figure 1A). Sequencing of the smaller band showed that this transcript
was an EGFR truncation that lacked the entire exon 4 sequence. Like
EGFRvIII, this in-frame splice variant generated a novel glycine residue
at the junction [19] (Figure 1B). This novel variant was named as de4
EGFR (GenBank accession number:HQ912715) to distinguish it from
wild-type EGFR (Figure 1C ). Further analysis of de4 EGFR mRNA
expression in tumor tissues was performed. However, the length of
de4 EGFR is very similar to that of EGFRwt, making it difficult to
observe. Moreover, because clinical samples such as tumor biopsies
may contain a small fraction of mutant genes and a large amount of
wild-type genes, a highly sensitive assay for mutant detection should
be applied [27]. Therefore, we designed a pair of variant-specific prim-
ers that amplified de4 EGFR but not wild-type EGFR (Figure 2A). The
results shown in Figure 2B indicated that both non–variant-specific
PCR and variant-specific PCR could obtain de4 EGFR amplicons,
but the bands for the de4 EGFR PCR products were clearer when using
the variant-specific primers. Using variant-specific PCR, we also ob-
served the presence of de4 EGFR in ovarian cancer tissues and prostate
cancer tissues but not in tissues adjacent to tumors or normal tissues
(Figures 2B and W1). A summary of the expression of de4 EGFR in
the examined tissues is shown in Figure 2C .
de4 EGFR Owns a Proliferation-Promoting Capacity and
an Enhanced Transformation Ability
To analyze the function of de4 EGFR, two cell lines commonly used
to study the function of EGFR, U87MG and NIH/3T3, were used.
U87MG and NIH/3T3 were stably transfected with GFP, EGFRwt,
or de4 EGFR. Growth curves demonstrated that, similar to EGFRwt,
overexpression of de4 EGFR significantly increased cell proliferation
(Figure 3A). Moreover, in the in vivo tumor formation assay, both
EGFRwt and de4 EGFR promoted tumor growth when compared
with GFP controls (Figure 3B). The effect of EGFRwt and de4 EGFR
on cell transformation was further evaluated by colony formation in soft
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agar (Figure 3C ). The colony sizes of de4 EGFR and EGFRwt trans-
fectants were comparable, although bigger than those of GFP trans-
fectants. However, more colony number was formed after de4 EGFR
overexpression than EGFRwt-expressing cells. Collectively, these find-
ings imply that de4 EGFR variant enhanced anchorage-independent
cell growth and tumor proliferation.
de4 EGFR Has a Higher Metastasis Potential in Comparison
to Wild-type EGFR
In vitro migration and invasion assays were performed to explore
whether de4 EGFR promoted the invasive capacity of tumor cells. A
transwell migration and invasion assay using U87MG transfectants
showed that EGFRwt induced a twofold increase in cell migration
and a threefold increase in cell invasion compared with the GFP control.
Intriguingly, de4 EGFR elicited even higher cell migration and invasion
rates (approximately three- and eightfold higher than the GFP control,
respectively) compared with EGFRwt (Figure 4A). Experiments using
NIH/3T3 transfectants showed similar results (Figure W2).
We then tried to confirm the metastasis-promoting capacity of de4
EGFR in vivo. U87MG transfectants were inoculated subcutaneously
into the right hind flank of BALB/c nude mice. Eight weeks later, the
mice were killed, and the lung weights were recorded. The results
showed that U87MG-de4 EGFR induced the most extensive metastasis
to the lungs, whereas cells bearing GFP or EGFRwt produced only
occasional and less extensive pulmonary nodules. The heavier tumor
burden caused by de4 EGFR in comparison to EGFRwt was readily
detectable by hematoxylin and eosin staining (Figure 4B). Importantly,
two of the eight mice that received U87MG de4 EGFR also exhibited
extrapulmonary metastases sites, including the diaphragm, the liver,
and the colon (Figure 4C ). In contrast, no extrapulmonary metastases
were observed in the GFP or EGFRwt groups (data not shown). These
results indicated that, when compared with EGFRwt, de4 EGFR
possessed significantly stronger tumor metastasis-promoting activities
both in vitro and in vivo.
de4 EGFR Undergoes Basal Autophosphorylation and
Constitutive Downstream Signaling
We next investigated potential mechanisms underlying the con-
tributions of de4 EGFR to tumorigenesis and metastasis. Considering
that exon 4 encodes an important part of the EGF-binding domain
[28,29], it was reasonable to speculate that the binding activity between
de4 EGFR and its ligands might be changed. Fluorescence-activated
Figure 1. Identification of de4 EGFR. (A) The discovery of de4 EGFR in glioma. The amplicon and the corresponding length of each EGFR
variant are shown by an arrow. The right panel shows the determined sequencing result of de4 EGFR. (B) Salient features of de4 EGFR.
The in-frame splicing removes exon 4 and creates a novel glycine residue at the splice junction. (C) Schematic representation of de4
EGFR variant. Deleted amino acid numbers are indicated. ECD indicates extracellular domain (S1, L1, S2, and L2 are subdomains); ICD,
intracellular domain; RD, regulatory domain; SP, signal peptide; TKD, tyrosine kinase domain; TM, transmembrane.
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cell sorter analysis using tetramethylrhodamine-labeled EGF showed
that, in contrast to wild-type EGFR, de4 EGFR had lost most of its
EGF-binding capability (Figure 5A). Because de4 EGFR retained
tumor-promoting capacity in our former experiments, we questioned
whether activation modes other than EGF-dependent stimulation were
present in cell lines expressing de4 EGFR.
Previous studies reported that EGFRvIII, the most common EGFR
mutant discovered to date, undergoes ligand-independent autophos-
phorylation, which mediates oncogenic signaling and transformation
[19,30]. We hypothesized that de4 EGFR undergoes a similar autophos-
phorylation. We observed higher tyrosine autophosphorylation at the
C-terminal of de4 EGFR (e.g., Tyr1068 andTyr1173) in a serum-starved
condition. By contrast, EGFRwt and de4 EGFR exhibited a similar
degree of tyrosine phosphorylation at Tyr992 and no phosphorylation
at Tyr1086 and Tyr845 (Figure 5B). When treated with EGF, the phos-
phorylation at all the tested tyrosine residues in EGFRwt increased dra-
matically, whereas in de4 EGFR, only the phosphorylation at Tyr992
changed with a slight up-regulation.
To further verify whether the basal phosphorylation of de4 EGFR
variant was due to intrinsic activation or enhanced sensitivity to EGF-
like ligands’ stimulation, U87MG cells expressing EGFRwt or de4
EGFR were treated with increasing EGF concentrations (Figure 5C).
The quantification of results illustrated that the phosphorylation of
EGFRwt ascended after the increased ligand concentrations. The phos-
phorylation of de4 EGFR underwent a small increase when the cells
were treated with 0.1 ng/ml of EGF. However, when cells were treated
with EGF at a higher concentration, the phosphorylation of de4 EGFR
was almost consistent. This observation indicates that intrinsic activa-
tion, rather than enhanced EGF sensitivity, may be responsible for the
relatively high basal phosphorylation of de4 EGFR variant.
Because basal phosphorylation of EGFR variants can be caused by
self-dimerization, dimerization of de4 EGFR was also investigated.
To acquire covalently conjugated receptor dimmers for immunoblot
analysis, cells were treated with the covalent cross-linking reagent bis
(sulfosuccinimidyl) suberate (BS3) and harvested. Results of immuno-
blot assay clearly showed that dimerization of de4 EGFR occurred in-
dependent of EGF treatment. By contrast, the dimer of EGFRwt only
formed in the presence of EGF (Figure 5D).
Considering the possibility that basal tyrosine activation may initiate
constitutive downstream signaling, general signaling pathways related to
EGFR were also examined. Activation of ERK and AKT by U87MG-
de4 EGFR in the absence of serumwas observed, although it was slightly
weaker than EGF-induced phosphorylation in U87MG-EGFR (Fig-
ure 5E). Moreover, the induction of JUN, an oncogenic transcription
factor that is mediated by EGFR activation, was detected in the
serum-starved condition or under EGF treatment. In the absence of
EGF stimulation, a relatively higher level of JUN was observed in de4
EGFR transfectants than that in EGFR transfectants. EGF treatment
increased JUN expression in EGFR transfectants but not in de4 EGFR
transfectants (Figure 5F ).
Reduction of E-cadherin Expression Contributes to the
Increased Invasiveness of Cell Lines Expressing de4 EGFR
It has been reported that E-cadherin, a 120-kDa transmembrane
glycoprotein located at the adherens junctions of epithelial cells, is often
downregulated in highly invasive, poorly differentiated carcinomas
[31]. In this study, we found that, in comparison to U87MG-GFP,
U87MG-EGFR had lower E-cadherin expression and U87MG-de4
EGFR had almost no E-cadherin expression in different culture con-
ditions (Figures 6A and W3).
Interestingly, the activation of EGFR generally results in the down-
regulation of E-cadherin–mediated cell-cell adhesion, accompanying
EGFR-dependent proliferation, and migration of tumor cells. Previous
studies reported that ERK activation inhibits E-cadherin expression;
however, activated EGFR and overexpression of Src, a downstream
target of EGFR, phosphorylate β-catenin at Y654 and then facilitate
Figure 2. de4 EGFR is observed in multiple cancer tissues. (A) Schematic of the PCR method used to detect the deletion of exon 4 in the
EGFR gene. (B) Detection of EGFRwt and de4 EGFR in gliomas by conventional and variant-specific PCR. (Partial results) The variant
amplicons shown here were sequenced. β-Actin served as an internal control. (C) Summary of the occurrence of de4 EGFR in several
cancer tissues. Method 1: detection by conventional PCR. Method 2: detection by variant-specific PCR. NA indicates not applicable.
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the loss of the association between E-cadherin and β-catenin [32,33]. In
addition to the ERK basal activation presented previously, the phos-
phorylation of β-catenin was also observed in tumor cells bearing de4
EGFR. As shown in Figure 6B, there was an increase in β-catenin phos-
phorylation at Y654 in U87MG-de4 EGFR with basal phosphoryla-
tion of EGFR as well as enhanced Src expression and activation but
no difference in total β-catenin concentration.
To further investigate the role of E-cadherin in the cell lines express-
ing EGFR and de4 EGFR, exogenous E-cadherin was introduced into
these transfectants (Figure 6B). As shown in Figure 6C , when E-cadherin
expression was rescued, the migration capacity of U87MG-EGFR and
U87MG-de4 EGFR decreased.
Discussion
In this study, we report a novel variant of EGFR. This variant, which
lacks the entire exon 4 sequence, is widely expressed in human tumors,
and it seems to be associated with tumorigenesis. Interestingly, all the
four de4 EGFR-positive gliomas belong to glioblastoma multiforme
(grade 4), suggesting that de4 EGFR is positively correlated to the
malignant degree of tumors. The joining of exons 3 and 5 generates
a truncated EGFR transcript that is only 135 bp less than the wild-type
human EGFR [34]. Because most clinical samples contain a high pro-
portion of normal cells or genes, it is difficult to distinguish this sort
of variant from the wild-type EGFR; this might be the reason why this
variant was not identified in previous studies. To distinguish de4 EGFR
protein from wild-type EGFR protein, we tried using the junction pep-
tide of de4 EGFR to immunize rabbits and mice to generate polyclonal
antibodies and monoclonal antibodies. Unfortunately, the antibodies we
obtained could not completely discriminate between de4 EGFR and
wild-type EGFR. Thus, detection of de4 EGFR at the protein level will
remain problematic until an appropriate antibody is prepared.
The human EGFR gene contains 28 exons and spans approximately
200 kb. Previous studies have reported several alternatively spliced
transcripts of EGFR, including the 1.8-kb transcript encoding soluble
receptors [34]. The de4 EGFR variant may be produced through alter-
native splicing that joins exon 3 and exon 5 in some instances. Another
possibility is that this variant transcript results from genomic deletion
[19]. However, in our preliminary study using genomic-specific prim-
ers, amplicons of de4 EGFR were not observed in the tested tissues
(data not shown), suggesting that the variant complementary DNA is
more likely to be generated as a consequence of alternative splicing.
A previous study reported that EGFR gene amplification frequently
occurred in gliomas [14]. We found that about half of the gliomas
tested possessed EGFR amplification (data not shown). Among the
four samples with de4 EGFR expression, only two samples carried
EGFR amplification (1.5-folds and 7.2-folds compared with normal
brains). Therefore, there seems no causal relationship between de4
EGFR expression and EGFR amplification.
It is well known that some EGFR variants with deletions in the ex-
tracellular domain cause increased malignancy in cells [15]. Our study
Figure 3. de4 EGFR promotes proliferation and transformation. (A) Growth curve showing the mitogenic activities of U87MG (bottom) and
NIH/3T3 (top) transfectants in vitro. Inset: immunoblot analysis of whole lysates of the NIH/3T3 and U87MG transfectants using an anti-EGFR
antibody. (B) Both EGFRwt and de4 EGFR promoted the proliferation of U87MG in vivo (n=5). The right panel shows a comparison of tumor
weight. (C) Colony formation in soft agar. NIH/3T3 cell derivatives (300/well) were cultured for 3 weeks. de4 EGFR transfected cells form the
most colonies. *P< .05, compared with the control. Error bars, SD. Photomicrographs of colonies are representative. Magnification, ×400.
The normality of each data setwas confirmed using the Levene test. Statistical datawere evaluated using an ANOVA. Comparisons between
two means were evaluated using the LSD method.
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indicates that de4 EGFR has the capacity to promote proliferation,
although no growth advantage over EGFRwt was observed. The reason
why de4 EGFR did not display proliferation-promotion advantage
over EGFRwt is rather complicated. One possibility is that, in the
presence of serum, wild-type EGFR itself can also induce strong cell
proliferation. Importantly, de4 EGFR has an enhanced transformation
capacity as well as a higher metastasis-promoting potential than wild-
type EGFR. Because de4 EGFR was also detected in human tumors
other than gliomas, the role of de4 EGFR in those tumors needs to
be studied further. In addition, clinical studies on the correlation
between de4 EGFR expression and prognosis in patients with such
tumors should be performed.
Dimerization and tyrosine phosphorylation on EGF binding are
important features of intact EGFR [35]. The extracellular domain
of EGFR consists of four domains: L1, S1, L2, and S2. Domains L1
and L2 form the main part of the EGF-binding pocket, whereas
S1 and S2 act as backbone structures [28,29]. A peptide composed
of 45-amino-acid residues that are encoded by exon 4 functions as
a hinge between the L1 and S1 domains (Figure 1C). Thus, the dele-
tion of exon 4 should affect the conformation of the EGF binding
Figure 4. de4 EGFR promotes invasion and metastasis in vitro and in vivo. (A) de4 EGFR enhances migration and invasion of U87MG
in vitro (quantified on the right). Magnification, ×100. Representative experiments are shown in triplicate along with SD. (B) de4 EGFR
promotes more severe spontaneous metastases after subcutaneous inoculation of U87MG transfectants. Left: Comparison of lung
lesions caused by three transfectants and hematoxylin and eosin staining of formalin-fixed lung sections. Magnification, ×40. Right:
Comparison of lung weight (tumor burden). Error bars, SD (n = 7/7/8). The normality of each data set was confirmed using the Levene
test. Statistical data were evaluated using an ANOVA. Comparisons between two means were evaluated using the LSD method.
(C) U87MG–de4 EGFR induced extrapulmonary metastatic foci in the diaphragm (left), liver (middle), and colon (right).
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region of EGFR and, accordingly, the receptor’s binding activity to
EGF. Interestingly, in the absence of ligand, de4 EGFR undergoes
self-dimerization and constitutive tyrosine phosphorylation at residues
Tyr1068 and Tyr1173. It seems that de4 EGFR acts as EGFRvIII in
its metastasis-promoting activities as well as ligand-independent auto-
phosphorylation and self-dimerization properties. However, unlike
EGFRvIII, de4 EGFRdid not show amore powerful capacity to promote
proliferation than wild-type EGFR. Molecular mechanisms underlying
the discrepancy on proliferation-promoting capacity between de4 EGFR
and EGFRvIII need further studies.
Because some tyrosine residues of de4 EGFR are constitutively phos-
phorylated without ligand activation, downstream signaling cascades
could be activated without EGF binding. We know that through the
recruitment of Grb2, Tyr1068 is associated with the activation of the
mitogen-activated protein kinase (MAPK)/ERK and phosphoinositide
3-kinase/AKT pathways [19,36,37]. Thus, its constitutive phosphory-
lation led to a significant increase in ERK phosphorylation and a small
increase in AKT phosphorylation. The expression of JUN, a down-
stream signaling molecule of ERK and AKT, was also upregulated in
de4 EGFR-transfected U87MG cells, leading to the enhancement of
transcriptional activity associated with cell proliferation and malignant
transformation (Figure 7).
It has been reported that EGFR activation may cause the dis-
mantling of cell-cell contacts by promoting the destabilization, the
down-regulation, and the endocytosis or subsequent degradation of
E-cadherins. Of note,MAPK activation is also involved in the negative
Figure 5. Oncogenic signaling of de4 EGFR. (A) Flow cytometry analysis for EGF-Rho binding affinity. Reactivity was tested on U87MG-
EGFR (left) and U87-de4 EGFR (middle). Expression of total EGFR was assessed first (right). Autofluorescence blanks are also shown (red).
(B) Tyrosine phosphorylation of EGFRwt and de4 EGFR treated with or without EGF for 8 minutes. Y1068 and Y1173 were phosphorylated
in the presence of de4 EGFR in the absence of EGF activation. GAPDH served as an internal control. (C) U87MG transfectants expressing
either EGFRwt or de4 EGFR were incubated with increasing EGF concentrations. The phosphorylation of Y1068 was analyzed by immuno-
blot analysis with the indicated antibodies. Phospho-EGFR levels were quantified according to band intensities. (D) Dimerization analysis
of EGFRwt and de4 EGFR. Cells were treated with or without EGF (100 ng/ml; 8 minutes) and incubated with or without a covalent cross-
linking reagent, BS3 (2 mM, 20 minutes). EGFR dimers and monomers are indicated, respectively. (E) General signaling pathways relating to
EGFR. ERK and AKT are activated in the presence of de4 EGFR. GAPDH served as an internal control. (F) The relative levels of JUN were
determined by immunoblot analysis. The bands were quantified according to band intensities. GAPDH served as an internal control.
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Figure 6. Reduction of E-cadherin–mediated cell-cell adhesion contributes to the increased migratory capacity of cell lines expressing
de4 EGFR. (A) E-cadherin expression levels in three U87MG transfectants. (B) Activation of EGFR and overexpressed Src induced phos-
phorylation of β-catenin. Numbers indicate normalized intensities of bands. Cells were serum-starved for 8 hours and then harvested.
(C) ExogenousE-cadherinwas successfully transfected intoU87MG-EGFRandU87MG–de4EGFR. EnhancedE-cadherin expression resulted
in decreased migratory capacity of U87MG-EGFR and U87MG-de4 EGFR. The normality of each data set was confirmed using the Levene
test. Statistical data were conducted using the t test method.
Figure 7. Model showing how de4 EGFR promotes cell malignancy. Unlike EGFRwt, de4 EGFR shows basal phosphorylation indepen-
dent of EGF stimulation. de4 EGFR likely enhances proliferation and transformation through constitutive activation of ERK/AKT and up-
regulation of the expression level of JUN in the absence of ligand stimulation. Conversely, de4 EGFR drives migration by down-regulation
of E-cadherin–mediated cell-cell adhesion through two different mechanisms. One involves constitutive activation of ERK and thus inhibits
E-cadherin expression. The other pathway includes β-catenin phosphorylation induced by overexpressed Src and basal activation of EGFR.
This leads to the destruction of E-cadherin/catenin adhesive complexes and hence facilitating cell migration.
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regulation of E-cadherin [32,38]. In this study, we verified that
E-cadherin is inversely related to cell invasion. Tumor cells expressing
de4 EGFR had limited expression of E-cadherin protein and increased
invasive activity, which was reduced by restoration of E-cadherin in
these cells. Furthermore, the limited E-cadherin expression that we
observed may be related to the constitutive tyrosine phosphorylation
of de4 EGFR and the continuous activation of the downstreamMAPK
pathway. In addition, β-catenin phosphorylation at Y654 also contrib-
utes to the destabilization of E-cadherin/catenin adhesive complexes,
which is potentially downregulated by EGFR and its downstream
target, Src [33,38]. It is likely that these different mechanisms play a
coordinated role in facilitating the loss of E-cadherin expression and
hence dismantling of cell-cell contacts. Regardless, the significantly de-
creased activity of E-cadherin revealed a potential explanation for the
potent migration-promoting ability of de4 EGFR variant (Figure 7).
EGFR is one of the most important cancer therapeutic targets dis-
covered to date. By the end of 2008, more than 10 EGFR-targeting
agents were in stages of advanced clinical development for the treat-
ment of human cancers. Two anti-EGFR monoclonal antibodies
(cetuximab and panitumumab) and two tyrosine kinase inhibitors di-
rected against EGFR (gefitinib and erlotinib) have been approved by
the US Food and Drug Administration and/or the EuropeanMedicines
Agency for the treatment of various human cancer types. However,
because EGFR is widely expressed in many human tissues, EGFR-
targeting therapies are likely to have adverse effects, including skin
toxicity and diarrhea [5,39]. Because EGFR variants are generally tumor-
specific, they may be more rational targets for anticancer therapy. Fur-
thermore, antibodies and vaccines selectively targeting these variants
should have lower toxicity [40]. For example, no significant toxicity
was found in the phase 1 clinical trial of mAb ch806 [23]. Therefore,
de4 EGFR is a promising therapeutic target, and therapeutics targeting
de4 EGFR should be developed and tested.
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Figure W2. de4 EGFR promotes the invasion andmigration of NIH/3T3 cells in vitro (quantified below). Magnification, ×100. Representative
experiments are shown in triplicate along with SD.
Figure W1. de4 EGFR expression was observed in ovarian cancer tissues (A) and prostate cancer/adjacent tissues (B). The variant-specific
PCR approach was used. β-Actin served as an internal control.
Figure W3. de4 EGFR induced potently downregulated expression of E-cadherin in the presence of serum or EGF and in the serum
starvation condition.
